Does the benefit justify the risk?
作者信息
Albertsen Peter C
出版信息
J Natl Cancer Inst. 2010 Jan 6;102(1):4-5. doi: 10.1093/jnci/djp427. Epub 2009 Dec 7.
PMID:19996059
Abstract
摘要
相似文献
1
Does the benefit justify the risk?
J Natl Cancer Inst. 2010 Jan 6;102(1):4-5. doi: 10.1093/jnci/djp427. Epub 2009 Dec 7.
2
Is hormone ablation still the right choice for advanced prostate cancer?
BJU Int. 2007 Jul;100 Suppl 2:36-9. doi: 10.1111/j.1464-410X.2007.06952.x.
3
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7.
4
[Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Arch Esp Urol. 2002 Sep;55(7):771-5.
5
Abiraterone and MVD3100 take androgen deprivation to a new level.
J Natl Cancer Inst. 2011 Feb 2;103(3):175-6. doi: 10.1093/jnci/djr014. Epub 2011 Jan 17.
6
[Clinics in prostate cancer].
Rinsho Byori. 2004 Jul;52(7):604-10.
7
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. doi: 10.1093/jnci/djm168. Epub 2007 Oct 9.
8
Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Urology. 2006 May;67(5):1084.e15-7. doi: 10.1016/j.urology.2005.11.015.
9
[And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
MMW Fortschr Med. 2009 Jul 23;151(30-33):72-3.
10
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23. doi: 10.1093/jnci/djs376.
Zotero 插件